Hidradenitis Suppurativa – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of hidradenitis suppurativa (HS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed incidence and prevalence of HS for each country, as well as annualized case counts projected to the national population. Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s HS forecast will answer the following questions:
- How many people in each of the major mature pharmaceutical markets have been formally diagnosed with HS?
- How does the severity of HS differ between newly diagnosed and existing prevalent HS cases?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts five HS patient populations, as follows:
- Diagnosed incident cases.
- Diagnosed prevalent cases.
- Diagnosed incident cases by severity.
- Diagnosed prevalent cases by severity.
- Diagnosed prevalent cases by site of major lesions.
Note: Coverage may vary by country.
Table of contents
- Hidradenitis Suppurativa - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of hidradenitis suppurativa)
- Diagnosed prevalent cases
- Diagnosed incident cases
- Diagnosed prevalent cases by severity
- Diagnosed incident cases by severity
- Diagnosed prevalent cases by site of major lesions
- Risk / protective factors applied to disease forecast models
- Reference materials
Madison Kircher, M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Kircher completed the CDC/CSTE Applied Epidemiology Fellowship program with the Minnesota Department of Health. She received her M.P.H. from the University of Wisconsin in Madison in 2020.
Sunali D. Goonesekera, S.M., Senior Manager, Epidemiology. Prior to joining Clarivate, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.